Capecitabine and temozolomide versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer.
Purpose To determine whether second-line therapy with capecitabine and temozolomide was superior to irinotecan, leucovorin and fluorouracil (FOLFIRI) in patients with RAS mutated, MGMT methylated metastatic colorectal cancer. Experimental design In this randomized, phase 2 trial, we enrolled patients with RAS mutated, MGMT methylated mCRC after failure of oxaliplatin-based regimen. Patients with centrally confirmed MGMT methylation were stratified by first-line progression-free survival and prior bevacizumab and randomized to either capecitabine plus temozolomide (arm A, CAPTEM) or FOLFIRI (arm B). The primary endpoint was progression-free survival analyzed on intention-to-treat basis, with 90% power and one-sided significance level of 0.05 to detect an increase of median time from 2 months in arm B to 4 months in arm A. Results Between November 2014 and May 2019, 86 patients were randomly assigned to arm A (n=43) or arm B (n=43). After a median follow-up of 30.5 months (IQR 12.2-36.3), 79 disease progression or death events occurred. Superiority of arm A was not demonstrated (one-sided p=0.223). Progression-free survival and overall survival were 3.5 (2.0-5.0) and 9.5 (8.2-25.8) in arm A versus 3.5 (2.3-6.1) and 10.6 (8.5-20.8) in arm B (HR=1.19 [0.82-1.72] and HR=0.97 [0.58-1.61]), respectively. Grade ≥3 treatment-related adverse events had higher incidence in arm B versus A (47.6% vs 16.3%), and quality of life was significantly worse in arm B. Patients with positive MGMT expression by immunohistochemistry did not benefit from CAPTEM. Conclusions Temozolomide-based therapy warrants further investigation in molecularly hyper-selected subgroups.